Core Viewpoint - The stock price of Renmin Tongtai has experienced significant fluctuations, with a cumulative increase of 20% over two consecutive trading days, leading to a classification of abnormal trading behavior according to Shanghai Stock Exchange regulations [1] Group 1: Stock Performance - The stock price of Renmin Tongtai has seen a continuous increase, with a total rise of 46.43% from November 10 to November 13, 2025, while the Shanghai Composite Index only increased by 0.80% during the same period [1] - The stock price increase is significantly higher than the cumulative rise of 4.53% in the pharmaceutical commercial sector (Shenwan) [1] Group 2: Company and Market Conditions - The company conducted a self-examination and confirmed, after consulting with its controlling shareholder, that there are no undisclosed major events or important information [1] - The company’s main business has not undergone significant changes, indicating that the stock price surge may be driven by market sentiment and irrational speculation, posing a risk of rapid decline [1]

人民同泰表示，公司股价涨幅已明显高于同期行业指数及上证指数，随时存在快速下跌风险。11月10日 至11月13日，公司股票连续4个交易日涨停，期间累计涨幅达46.43%，同期上证指数累计涨幅0.8%，医 药商业(申万)累计涨幅4.53%。公司主营业务未发生重大变化，股价短期内连续上涨，存在市场情绪过 热、非理性炒作风险，随时存在快速下跌风险。 北京商报讯(记者丁宁)11月13日晚间，人民同泰（600829）发布公告称，公司股票价格于11月12日、11 月13日连续2个交易日内日收盘价格涨幅偏离值累计达到20%，根据上交所的有关规定，属于股票交易 异常波动情形。经公司自查，并向公司控股股东哈药集团股份有限公司、间接控股股东哈药集团有限公 司询证，不存在应披露而未披露的重大事项或重要信息。 ...

Major Events - Guotai Group acquired 100% equity of Beikuan Baomao for 110 million yuan through public bidding [3] - People's Tongtai stock price has a risk of rapid decline after a 46.43% increase over four consecutive trading days [4] - Huasheng Lithium's revenue increased by 62% in the first three quarters, but the company still reported a loss of 102.97 million yuan [5] - Haizike received approval for clinical trials of the innovative drug HSK39297 for age-related macular degeneration [6] - Angli Education postponed its response to an asset acquisition inquiry for no more than five trading days [7] - Shuguang Co. terminated its plan to issue shares to specific targets, and the Shanghai Stock Exchange has decided to terminate the review [8] Performance Overview - JD Group reported third-quarter revenue of 299.1 billion yuan, a year-on-year increase of 14.9% [9] - SMIC's third-quarter net profit was 1.517 billion yuan, up 43.1% year-on-year [10] - Tencent Holdings achieved third-quarter revenue of 192.87 billion yuan, a 15% year-on-year growth [11] - Lu'an Huaneng's coal sales in October reached 3.78 million tons, a year-on-year increase of 3.28% [12] Shareholding Changes - Haicheng Bangda's director plans to reduce holdings by no more than 0.97% due to personal financial needs [13] - Qisheng Technology's major shareholder reduced their stake to 40% after a transaction [14] - Tianwei Electronics' major shareholder reduced their stake to below 5% [15] - Zhongzi Technology's major shareholders collectively reduced their stake by 1.35% [16] Major Contracts - Lizhong Group's subsidiary received project confirmations with an estimated total sales of approximately 1.135 billion yuan [18] - Anhui Construction's subsidiary won a project bid worth 1.753 billion yuan [19]

Group 1 - A total of 106 stocks in the A-share market hit the daily limit, with 86 stocks hitting the limit after excluding 20 ST stocks, resulting in an overall limit-up rate of 70.2% [1] - Victory Co., Ltd. had the highest limit-up order volume at 764,100 hands, while 36 stocks had limit-up order funds exceeding 100 million yuan, with Tinci Materials, Furui Shares, and Suda Shares leading in order funds at 573 million yuan, 451 million yuan, and 428 million yuan respectively [1][2] Group 2 - Tinci Materials closed at 47.20 yuan with a turnover rate of 10.02%, achieving a limit-up order volume of 121,400 hands and order funds of 573 million yuan, driven by long-term contracts for electrolytes and lithium hexafluorophosphate [2] - Furui Shares closed at 10.51 yuan with a turnover rate of 1.92%, achieving a limit-up order volume of 429,500 hands and order funds of 451 million yuan, attributed to electrolyte additives and equity unfreezing [2] - Suda Shares closed at 48.84 yuan with a turnover rate of 22.11%, achieving a limit-up order volume of 87,600 hands and order funds of 428 million yuan, supported by coal equipment and overseas expansion [2]

Major Announcements - Guotai Group acquired 100% equity of Beikuan Baomao for 110 million yuan through public bidding [3] - People's Tongtai stock price has risen for four consecutive trading days, with a total increase of 46.43%, indicating potential rapid decline risk due to market sentiment [4] - Huasheng Lithium's stock price has deviated significantly, with a 62% revenue increase in the first three quarters, but still reporting a net loss of 10.3 million yuan [5] - Haishi Ke received approval for clinical trials of innovative drug HSK39297 for age-related macular degeneration, showing high development potential [6] - Angli Education postponed its response to an asset acquisition inquiry for no more than five trading days [7] - Shuguang Co. terminated its plan to issue shares to specific targets, with the Shanghai Stock Exchange halting the review [8] Performance Overview - JD Group reported third-quarter revenue of 299.1 billion yuan, a year-on-year increase of 14.9%, with net profit of 5.3 billion yuan [10] - SMIC achieved third-quarter net profit of 1.517 billion yuan, a 43.1% year-on-year increase, with revenue of 17.162 billion yuan [11][12] - Tencent Holdings reported third-quarter revenue of 192.87 billion yuan, a 15% year-on-year increase, with operating profit of 72.57 billion yuan [13] - Lu'an Huaneng's coal sales in October reached 3.78 million tons, a year-on-year increase of 3.28% [14] Shareholding Changes - Haicheng Bangda's director Wang Xiping plans to reduce his holdings by up to 0.97% due to personal financial needs [16] - Qisheng Technology's major shareholder reduced their stake to 40% through a block trade [17] - Tianwei Electronics' major shareholder Xie Kai reduced his holdings to below 5% [18] - Zhongzi Technology's major shareholders collectively reduced their stake by 1.35% [19] Major Contracts - Lichong Group's subsidiaries received project confirmations with an estimated total sales of approximately 1.135 billion yuan [21] - Anhui Construction's subsidiary won a project bid worth 1.753 billion yuan [22]

New Stock Issuance - Cash option declaration period for Hangzhou Steam Turbine (200771) is from November 19 to November 25, 2025[1] - Acquisition request period for Hailianxun (300277) is from November 12 to November 18, 2025[1] Trading Alerts - Severe abnormal fluctuation reported for Haike Xinyuan (301292) on November 11, 2025[1] - Abnormal fluctuation noted for ST Yuancheng (603388) on November 11, 2025[1] Company Announcements - Announcement for Tianji Co., Ltd. (002759) on November 13, 2025[1] - Announcement for Huatong Technology (688109) on November 13, 2025[1] Other Notable Events - ST Meigu (000615) reported on November 13, 2025[1] - ST Zhongdi (000609) reported on November 13, 2025[1]

证券代码：600829 证券简称：人民同泰 编号：临 2025-032 哈药集团人民同泰医药股份有限公司 股票交易异常波动暨风险提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 哈药集团人民同泰医药股份有限公司（以下简称"公司"）股票价格于 2025 年 11 月 12 日、11 月 13 日连续 2 个交易日内日收盘价格涨幅偏离值累计达到 20%，根据上海证券 交易所的有关规定，属于股票交易异常波动情形。经公司自查，并向公司控股股东哈药集团 股份有限公司、间接控股股东哈药集团有限公司询证，不存在应披露而未披露的重大事项或 重要信息。 公司股价涨幅已明显高于同期行业指数及上证指数，随时存在快速下跌风险。2025 年 11 月 10 日至 2025 年 11 月 13 日，公司股票连续 4 个交易日涨停，期间累计涨幅达 46.43%， 同期上证指数累计涨幅 0.80%，医药商业（申万）累计涨幅 4.53%。公司主营业务未发生重 大变化，股价短期内连续上涨，存在市场情绪过热、非理性炒作风险，随时存在快速下跌 ...

智通财经APP讯，人民同泰(600829.SH)发布股票交易异常波动暨风险提示公告称，公司股价涨幅已明 显高于同期行业指数及上证指数，随时存在快速下跌风险。2025年11月10日至2025年11月13日，公司股 票连续4个交易日涨停，期间累计涨幅达46.43%，同期上证指数累计涨幅0.80%，医药商业(申万)累计涨 幅4.53%。公司主营业务未发生重大变化，股价短期内连续上涨，存在市场情绪过热、非理性炒作风 险，随时存在快速下跌风险。 ...

Core Viewpoint - The company experienced significant stock price fluctuations, with a cumulative increase of 20% from November 12 to 13, indicating abnormal volatility [1] Financial Performance - For the first three quarters of 2025, the company's revenue was 784,592.89 million, representing a year-on-year increase of 2.19% [1] - The net profit for the same period was 11,187.65 million, showing a year-on-year decline of 45.69% [1] Stock Performance - From November 10 to 13, the company's stock price hit the daily limit for four consecutive days, with a total increase of 46.43%, outperforming both the Shanghai Composite Index and the industry index during the same period [1] - As of November 12, the company's rolling price-to-earnings ratio was 60.84, significantly higher than the industry average of 18.75 [1] Risk Disclosure - The company has indicated potential risks related to trading and declining performance [1]

Core Viewpoint - The stock of Renmin Tongtai (600829.SH) experienced a significant increase, with a cumulative rise of 46.43% over four consecutive trading days, while the Shanghai Composite Index only rose by 0.80% during the same period [1] Company Summary - The main business activities of the company, which include pharmaceutical wholesale, retail, logistics services, and medical services, have not undergone any significant changes [1] - The company has confirmed that its operational activities are normal and there are no undisclosed significant information [1] Market Context - The recent surge in stock price may indicate an overheated market sentiment and irrational speculation, posing a risk of a rapid decline [1]